Cyclosporin A

ApprovedSmall molecule

Novartis

Cyclosporin A is one of 434 small molecule programs targeting Aplastic Anemia. It is currently in Approved.

Indications

Total Trials

Active Trials

433

Competitors

Pipeline

Status by Indication[3][1]

Indication

Aplastic AnemiaActive, not recruiting

Tic DisorderActive, not recruiting

HistiocytosisActive, not recruiting

Dry Eye SyndromeActive, not recruiting

Kidney TransplantActive, not recruiting

PneumoniaActive, not recruiting

MiscarriageActive, not recruiting

Myelodysplastic SyndromeActive, not recruiting

Breast CancerActive, not recruiting

PsoriasisActive, not recruiting

Aplastic AnemiaPhase 2

Active, not recruiting

Tic DisorderPhase 2

Active, not recruiting

HistiocytosisPhase 1/Phase 2

Active, not recruiting

Dry Eye SyndromePhase 2

Active, not recruiting

Kidney TransplantPhase 3

Active, not recruiting

PneumoniaPhase 1/Phase 2

Active, not recruiting

MiscarriagePhase 2/Phase 3

Active, not recruiting

Myelodysplastic SyndromePhase 2

Active, not recruiting

Breast CancerPhase 1

Active, not recruiting

PsoriasisApproved

Active, not recruiting

Showing 10 of 15 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Cyclosporin A

Novartis

Approved

1 2

Megace

Bristol-Myers Squibb

Preclinical

4 3

Cymbalta

Alnylam Pharmaceuticals

Preclinical

3 4

MS Contin

Merck & Co.

Preclinical

2 5

Zolymbus

AbbVie

Preclinical

1 6

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 7

Effexor

WWyeth-Lederle Vaccines

Preclinical

2 8

Recentin

NNational Cancer Institute (NCI)

Preclinical

2 9

Spravato

WWim Janssens

Preclinical

2 10

Avastin

Roche

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Recruiting

Aplastic Anemia

NCT06802055

Q4 2027

Post-ApprovalNot yet recruiting

Psoriasis

NCT04239859

Post-ApprovalRecruiting

Psoriasis

NCT04537689

Clinical

Trials by Indication[1]

Psoriasis2 trials

Outcomes With Treatment and Withdraw of Ixekizumab in Patients With Plaque Psoriasis

Recruiting·SSingapore General Hospital·Phase 4·NCT04537689·40 enrolled

Outcomes With Treatment and Withdraw of Secukinumab in Patients With Plaque Psoriasis

Not yet recruiting·SSingapore General Hospital·Phase 4·NCT04239859·40 enrolled

Renal Transplant2 trials

Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT00114777·595 enrolled

Polymorphism of the Cytochrome P450-system in Renal Transplants

Completed·UUniversity Hospital Schleswig-Holstein··NCT00223054·200 enrolled

Hematopoietic Stem Cell Transplantation2 trials

A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From Young Non-first-degree and Older First-degree Donors in Hematological Malignancies

Recruiting·FFirst Affiliated Hospital of Zhejiang University·Phase 3·NCT04547049·176 enrolled

Feasibility of Haploidentical Hematopoietic Stem Cell Transplantation Using CAMPATH-1H

Completed·TTehran University of Medical Sciences·Phase 1·NCT00458250·10 enrolled

Heart Transplantation2 trials

Exchange of Azathioprine by Mycophenolatmofetile and Cyclosporine A Dose Reduction After Heart Transplantation

Completed·HHannover Medical School·N/A·NCT00359814·23 enrolled

Withdrawal of Steroids, Cyclosporine A Dose Reduction and Switch to Mycophenolatmofetile After Heart Transplantation

Completed·HHannover Medical School·N/A·NCT00359658·40 enrolled

Kidney Transplant2 trials

Comparison of CNI-based Regimen Versus CNI-free Regimen in Kidney Transplant Recipients.

Terminated· Novartis logo

Novartis·Phase 4·NCT00332839·93 enrolled

12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant Patients

Completed· Novartis logo

Novartis·Phase 3·NCT01843348·612 enrolled

23 more indications

Sjogren's Syndrome1 trial

Cyclosporine A in the TReatment of Interstitial Pneumonitis Associated With Sjogren's Syndrome

Unknown status·PPeking University People's Hospital·Phase 4·NCT02370550·240 enrolled

Atopic Dermatitis1 trial

Optimization of Cyclosporin in Atopic Dermatitis Through Multiomic Predictive Models of Treatment Response

Unknown status·IInstituto de Investigación Hospital Universitario La Paz·Phase 4·NCT05692843·100 enrolled

Stem Cell Transplant1 trial

Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant

Completed·MMasonic Cancer Center, University of Minnesota·Phase 1/2·NCT00303667·50 enrolled

Myelodysplastic Syndrome1 trial

Treatment of Myelodysplastic Syndrome (MDS) With Cytokine-Immunotherapy for Low-Risk MDS

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00520468·15 enrolled

Immune Thrombocytopenia1 trial

A Multicenter Investigation of Recombinant Human Thrombopoietin (rhTPO) Combining Cyclosporin A Versus Cyclosporin A in Management of Steroid-Resistant/Relapsed Immune Thrombocytopenia （ITP）

Withdrawn·SShandong University·Phase 3·NCT02203422

Tocilizumab1 trial

A Single-arm Trial of Prophylactic Tocilizumab for Acute GVHD Prevention After Haploidentical HSCT.

Unknown status·YYi Luo·Phase 2·NCT04688021·46 enrolled

Uveitis1 trial

Cyclosporin Implant to Treat Uveitis

Completed·NNational Eye Institute (NEI)·Phase 1·NCT00001737·10 enrolled

Aplastic Anemia1 trial

Efficacy and Safety of Sirolimus With or Without Cyclosporin A in Chinese Patients With Aplastic Anemia Refractory/Intolerant to Cyclosporin A

Recruiting·PPeking Union Medical College Hospital·Phase 2·NCT06802055·40 enrolled

Histiocytosis1 trial

Treatment of Familiar Lymphohistiocytosis

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 1/2·NCT02472054·29 enrolled

Renal Transplant Recipients1 trial

Study to Evaluate the Efficacy, Safety and Tolerability of Everolimus in de Novo Renal Transplant Recipients Participating in the Eurotransplant Senior Program

Terminated· Novartis logo

Novartis·Phase 4·NCT00956293·207 enrolled

Dry Eye Syndrome1 trial

Treatment of Dry Eye Syndrome With Cyclosporin A Eye Drops

Completed·NNational Eye Institute (NEI)·Phase 2·NCT00001731·30 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of rhTPO in Combination With Cyclosporine Versus Cyclosporine Alone in the Treatment of TD-NSAA

Not yet recruiting·PPeking Union Medical College Hospital·Phase 4·NCT06525948·54 enrolled

Miscarriage1 trial

Use of Cyclosporin A for the Treatment of Recurrent Miscarriage

Unknown status·FFudan University·Phase 2/3·NCT02706470·384 enrolled

Pneumonia1 trial

Cyclosporine A Plus Low-steroid Treatment in COVID-19 Pneumonia

Unknown status·IInstituto de Seguridad y Servicios Sociales de los Trabajadores del Estado·Phase 1/2·NCT04540926·200 enrolled

Primary Biliary Cholangitis1 trial

Mycophenolate Mofetil Versus Cyclosporin A in the Treatment of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome Due to Nonresponse to Standard Therapy

Unknown status·WWest China Hospital·Phase 4·NCT04376528·89 enrolled

Behcet's Disease1 trial

Interferon-alpha2a Versus Cyclosporin A for Severe Ocular Behcet's Disease (INCYTOB)

Completed·UUniversity Hospital Tuebingen·Phase 3·NCT00167583·37 enrolled

Hematologic Malignancy1 trial

Allo-HSCT With Alternative Donor in Treatment of Hematologic Malignancy

Completed·NNanfang Hospital, Southern Medical University·N/A·NCT02487069·876 enrolled

Outcome1 trial

Outcomes of Patients After Allo-HSCT With Decitabine and NAC

Unknown status·TThe First Affiliated Hospital of Soochow University·Phase 3·NCT04945096·100 enrolled

Breast Cancer1 trial

Breast/Cyclosporin A/TNBC (Triple Negative Breast Cancer)

Withdrawn·—·Phase 1·NCT06246786

Tic Disorder1 trial

Stem Cell Transplant for Immunologic or Histiocytic Disorders

Completed·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00176865·19 enrolled

Nephropathy1 trial

Drug Therapy in Lupus Nephropathy

Completed·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT00001212·45 enrolled

Recurrent1 trial

Alitretinoin vs Cyclosporine in Severe Recurrent Vesicular Hand Eczema

Unknown status·UUniversity Medical Center Groningen·Phase 3·NCT03026946·76 enrolled

Graft Versus Host Disease1 trial

Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant

Completed·MMassachusetts General Hospital·Phase 1·NCT00513474·46 enrolled

Sources

References

[1]
ClinicalTrials.gov — 33 trial records for Cyclosporin A. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cyclosporin A compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cyclosporin A. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Novartis

Cyclosporin A

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q4 2027

Trials by Indication[1]

Psoriasis2 trials

Renal Transplant2 trials

Hematopoietic Stem Cell Transplantation2 trials

Heart Transplantation2 trials

Kidney Transplant2 trials

Sjogren's Syndrome1 trial

Atopic Dermatitis1 trial

Stem Cell Transplant1 trial

Myelodysplastic Syndrome1 trial

Immune Thrombocytopenia1 trial

Tocilizumab1 trial

Uveitis1 trial

Aplastic Anemia1 trial

Histiocytosis1 trial

Renal Transplant Recipients1 trial

Dry Eye Syndrome1 trial

Efficacy and Safety1 trial

Miscarriage1 trial

Pneumonia1 trial

Primary Biliary Cholangitis1 trial

Behcet's Disease1 trial

Hematologic Malignancy1 trial

Outcome1 trial

Breast Cancer1 trial

Tic Disorder1 trial

Nephropathy1 trial

Recurrent1 trial

Graft Versus Host Disease1 trial

References

Drug Info

Quick Facts

Related News